Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow NRX Pharmaceuticals, Inc.

Get SEC filing alerts via email and in your feed for NRX Pharmaceuticals, Inc.

NRXP NRXPW

NRX Pharmaceuticals, Inc.

About NRX Pharmaceuticals, Inc.

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders such as suicidal depression, bipolar disorder, PTSD, and chronic pain. Its key products include NMDA receptor modulators like NRX-100 and NRX-101, targeting rapid relief of suicidality and depression. The company also operates HOPE Therapeutics, a care delivery platform with clinics treating psychiatric conditions, integrating innovative drug development with patient care.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from NRX Pharmaceuticals, Inc.

1
1
NRX Pharmaceuticals, Inc. NRX Pharmaceuticals Reports $1.1M Revenue in Q1 2026, Net Loss Improves to $1.4M

Via official filing (AI summary) | 19 days ago | 0 comments

2
1
NRX Pharmaceuticals, Inc. NRX Pharmaceuticals Reports Fiscal Year 2025 Results and Advances Drug Pipeline

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
NRX Pharmaceuticals, Inc. NRX Pharmaceuticals Reports Q3 2025 Financial Results with Increased Losses and First Revenue from Dura Medical Acquisition

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
NRX Pharmaceuticals, Inc. NRX Pharmaceuticals Reports $17.6 Million Net Loss in Q2 2025, Expands Drug Development Pipeline

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
NRX Pharmaceuticals, Inc. NRX Pharmaceuticals Reports $5.5 Million Net Loss and Progress in Drug Development for Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
NRX Pharmaceuticals, Inc. NRx Pharmaceuticals Reports $25.1 Million Net Loss for 2024, Initiates New Drug Applications

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
NRX Pharmaceuticals, Inc. NRX Pharmaceuticals Reports Improved Financials, Advances Lead Drug Candidates

Via official filing (AI summary) | over 1 year ago | 0 comments